Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 261

Similar articles for PubMed (Select 6614959)

1.

Intra-arterial reserpine for Raynaud's syndrome. Systemic reactions without therapeutic benefit.

Surwit RS, Gilgor RS, Duvic M, Allen LM, Neal JA.

Arch Dermatol. 1983 Sep;119(9):733-5.

PMID:
6614959
2.

Le Phénomène de Raynaud.

Latulippe L.

Can Fam Physician. 1983 Feb;29:296-299. French.

3.

A Note on "Sensory Tetany," "Vasomotor Tetany," Acroparaesthesia, and Raynaud's Symptoms.

Weber FP.

Br Med J. 1911 Feb 25;1(2617):434-5. No abstract available.

4.

A case of Raynaud's disease-like condition of unusual severity following intramuscular quinine injections.

HALAWANI A, NOUR-EL-DIN G.

J Egypt Med Assoc. 1946 Jan-Feb;29(1-2):84-9. No abstract available.

PMID:
20242825
5.

Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.

Rosato E, Letizia C, Proietti M, Aversa A, Menghi G, Rossi C, Torella E, Cotesta D, Petramala L, Bruzziches R, Spera G, Pisarri S, Salsano F.

J Biol Regul Homeost Agents. 2009 Jan-Mar;23(1):23-9.

PMID:
19321043
6.

Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.

Fregene A, Ditmars D, Siddiqui A.

J Hand Surg Am. 2009 Mar;34(3):446-52. doi: 10.1016/j.jhsa.2008.11.026.

PMID:
19258141
7.

MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.

Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM.

Arthritis Rheum. 2009 Mar;60(3):870-7. doi: 10.1002/art.24351.

8.

Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication.

De LaVega AJ, Derk CT.

Expert Opin Investig Drugs. 2009 Jan;18(1):23-9. doi: 10.1517/13543780802525100 . Review.

PMID:
19053879
9.

Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.

Colakoğlu M, Cobankara V, Akpolat T.

Ann Pharmacother. 2007 Sep;41(9):1544-7. Epub 2007 Jul 31.

PMID:
17666574
10.
12.

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.

Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, Novo S.

Rheumatology (Oxford). 2006 Aug;45(8):999-1004. Epub 2006 Feb 16.

13.

Mechanisms of Raynaud's disease.

Cooke JP, Marshall JM.

Vasc Med. 2005 Nov;10(4):293-307. Review.

PMID:
16444858
14.

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.

Fries R, Shariat K, von Wilmowsky H, Böhm M.

Circulation. 2005 Nov 8;112(19):2980-5.

15.

Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil.

Baumhaekel M, Scheffler P, Boehm M.

Microvasc Res. 2005 May;69(3):178-9.

PMID:
15896360
16.
17.

Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.

Stoyneva Z.

Auton Neurosci. 2004 Nov 30;116(1-2):62-8.

PMID:
15556839
18.

Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding.

Anderson JE, Held N, Wright K.

Pediatrics. 2004 Apr;113(4):e360-4.

PMID:
15060268
19.

Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.

Kanetaka T, Komiyama T, Onozuka A, Miyata T, Shigematsu H.

Eur J Vasc Endovasc Surg. 2004 Apr;27(4):414-6.

PMID:
15015193
20.

[Clinical experience with reserpine therapy of heart disease].

TOSETTI D.

Gazz Med Ital. 1958 Aug;117(8):355-9. Italian. No abstract available.

PMID:
13574401
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk